{"product_id":"product_c1e17aef-8bd1-46df-85a0-32c3705121b1","title":"Life Pro - BERBERINE | 90caps (500MG)","description":"\u003ch2 class=\"text-text-100 mt-3 -mb-1 text-[1.125rem] font-bold\"\u003eAbout the Product\u003c\/h2\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eLife Pro Nutrition Berberine 500 mg is a food supplement in VCAPS vegetable capsules based on dry extract of Berberis vulgaris root (barberry) standardised to 97% berberine hydrochloride (berberine HCl), providing 500 mg of extract (485 mg of pure berberine HCl) per capsule. Berberine is an isoquinoline alkaloid with one of the most robust clinical evidence bases among phytotherapeutic compounds, with dozens of randomised controlled clinical trials documenting effects on insulin sensitivity, postprandial glycaemia, lipid profile (LDL cholesterol, triglycerides), blood pressure, and gut microbiota. The formula is minimalistic: a single ingredient (Berberis vulgaris extract), without unnecessary additives. 1 capsule 2 to 3 times\/day before meals = 1000 to 1500 mg\/day. 90 vegetable capsules (30 to 45 days). Vegan. Gluten-free, lactose-free.\u003c\/p\u003e\n\u003ch2 class=\"text-text-100 mt-3 -mb-1 text-[1.125rem] font-bold\"\u003eBenefits\u003c\/h2\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBerberine: the phytotherapeutic alkaloid with the widest range of clinically documented metabolic and cardiovascular effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBerberine (C₂₀H₁₈NO₄⁺) is a yellow isoquinoline alkaloid present mainly in the roots and bark of plants of the genus Berberis (barberry) and other plants such as Coptis chinensis (goldthread), Hydrastis canadensis (goldenseal), and Phellodendron amurense. It has been used in traditional Chinese and Ayurvedic medicine for over 2000 years, mainly as an intestinal antimicrobial and anti-inflammatory agent. Modern pharmacological research has identified AMPK (AMP-activated protein kinase), the enzyme considered the \"central switch of cellular metabolism,\" as the primary molecular target of berberine: berberine activates AMPK by inhibiting complex I of the mitochondrial respiratory chain, which results in an increase in the intracellular AMP\/ATP ratio, which in turn activates AMPK. This AMPK activation has downstream cascade effects that include increased glucose uptake by muscle (via GLUT4), inhibition of hepatic gluconeogenesis (via inhibitory phosphorylation of TORC2), increased fatty acid oxidation (via inhibition of ACC), reduced cholesterol synthesis (via inhibition of HMGCR), and improved insulin sensitivity (via reduced inhibitory phosphorylation of IRS-1). This mechanism of action via AMPK is mechanistically identical to that of metformin (the first-line drug for type 2 diabetes), which has led to berberine often being compared to metformin in terms of efficacy for glycaemic control.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGlycaemic control and insulin sensitivity: the comparison with metformin in clinical trials:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe meta-analysis by Yin et al. (2008), published in Metabolism: Clinical and Experimental with data from 3 randomised controlled studies and 291 participants with type 2 diabetes, showed that berberine (1500 mg\/day, 3 months) reduced fasting glucose by 1.84 mmol\/L (33 mg\/dl), postprandial glucose by 2.69 mmol\/L (48 mg\/dl), and glycated haemoglobin (HbA1c) by 0.71%, with efficacy comparable to that of metformin (HbA1c reduction of 0.67%) and glipizide (sulfonylurea). The Zhang et al. (2008) study published in the Journal of Clinical Endocrinology and Metabolism with 116 patients with type 2 diabetes and dyslipidaemia documented significant reductions in HbA1c, fasting insulin, LDL-cholesterol, triglycerides, and apoB compared to placebo, with acceptable safety and tolerability. The meta-analysis by Liang et al. (2019), published in Frontiers in Pharmacology with 27 controlled clinical trials, confirmed significant and consistent reductions in fasting glucose, HbA1c, HOMA-IR, and fasting insulin in multiple populations, including pre-diabetics, type 2 diabetics, and individuals with metabolic syndrome.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eHypolipidaemic effect: a distinct mechanism from statins with a solid evidence base:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIn addition to its effects on glycaemia, berberine has a documented effect on the lipid profile. The mechanism of its hypolipidaemic effect is distinct from that of statins: instead of directly inhibiting HMG-CoA reductase, berberine increases the expression of the hepatic LDL receptor (LDLR) by a post-transcriptional mechanism (stabilisation of LDLR mRNA via inhibition of the RNA-binding protein PCSK9 and MRNA-degrading enzymes), which increases hepatic uptake of LDL from plasma. The study by Kong et al. (2004), published in Nature Medicine, identified this mechanism and sparked interest in the scientific community given that statins have the opposite effect on LDLR expression (statins increase transcriptional expression of LDLR, while berberine stabilises existing mRNA). The meta-analysis by Dong et al. (2013), published in Evidence-Based Complementary and Alternative Medicine, with 11 clinical trials and 874 participants, documented significant reductions in LDL (-0.65 mmol\/L), triglycerides (-0.50 mmol\/L), total cholesterol (-0.61 mmol\/L), and apoB with berberine compared to placebo.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular health: mechanisms of vascular protection beyond the lipid profile:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIn addition to its effects on lipids and glycaemia, berberine has multiple direct effects on cardiovascular health documented in preclinical and clinical studies: moderate antihypertensive activity (via inhibition of angiotensin-converting enzyme, via activation of endothelial nitric oxide synthase which increases the production of vasodilatory NO, and via anti-inflammatory properties that reduce endothelial dysfunction); antiplatelet activity (inhibition of platelet aggregation via inhibition of COX-1 and phospholipase C); antiarrhythmic activity (via blockade of HERG potassium channels, which prolong the cardiac refractory period); and anti-inflammatory activity on the vascular wall (inhibition of NF-κB and reduction of CRP, IL-6, and TNF-α).\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGut microbiota and digestive health: the lesser-known effects of berberine:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBerberine has documented broad-spectrum antimicrobial activity, which originally justified its ancient use for intestinal infections. In the context of modern medicine, this property translates into a modulation of the gut microbiota: berberine inhibits the growth of pathogenic bacteria (including Helicobacter pylori, Salmonella, Shigella, pathogenic E. coli, Candida albicans) while having relatively neutral or positive effects on beneficial commensal bacteria of the Lactobacillus and Bifidobacterium genera. Recent studies suggest that part of berberine's metabolic effects (on glycaemia and lipids) may be precisely mediated by this modulation of the gut microbiota, given that the microbiome has a direct impact on glucose and bile acid metabolism.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003e97% berberine HCl: the most widely used form in clinical trials, with verifiable standardisation:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBerberine hydrochloride (berberine HCl) is the most soluble and stable salt form of berberine, and the form used in the vast majority of clinical trials. Standardisation to 97% ensures that 97% of the weight of Berberis vulgaris extract is effectively berberine HCl, with the remaining 3% corresponding to other minor alkaloids of the extract (palmatine, coptisine) and process excipients. This high standardisation ensures a consistent and verifiable dose of active berberine per capsule, unlike unstandardised Berberis vulgaris extracts where the berberine content can vary widely between batches.\u003c\/p\u003e\n\u003ch2 class=\"text-text-100 mt-3 -mb-1 text-[1.125rem] font-bold\"\u003eUses\u003c\/h2\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eRecommended dose:\u003c\/strong\u003e Take 1 capsule 2 to 3 times\/day before main meals (breakfast, lunch, and dinner). Taking it before meals (15 to 30 minutes before) is important for two reasons: it maximises the availability of berberine in the digestive tract during the absorption of carbohydrates from the meal, enhancing its effect in attenuating the postprandial glycaemic peak; and it distributes the total daily dose into multiple intakes, which is important given berberine's relatively short half-life (4 to 6 hours) that requires fractional dosing to maintain stable plasma levels.\u003c\/p\u003e","brand":"Life Pro","offers":[{"title":"Default Title","offer_id":52705358709083,"sku":null,"price":28.9,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1005\/0250\/3771\/files\/LifePro-Berberine500mg90Vegancaps.png?v=1776631702","url":"https:\/\/brothers-club.com\/en\/products\/product_c1e17aef-8bd1-46df-85a0-32c3705121b1","provider":"Brother's Club","version":"1.0","type":"link"}